MINI FUTURE LONG - ELI LILLY & CO | Market Closed - Euronext Paris 12:09:06 2024-05-22 EDT | ||
| 5.271 EUR | -1.14% |
|
| Current month | +8.22% | ||
| 1 month | +31.01% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-22 | 5.271 | -1.14% |
| 24-05-21 | 5.332 | +9.06% |
| 24-05-20 | 4.889 | +4.24% |
| 24-05-17 | 4.69 | -2.72% |
| 24-05-16 | 4.821 | -0.52% |
Real-time Euronext Paris
Last update May 22, 2024 at 12:09 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| OO5NB | |
| ISIN | NLBNPNL2OUQ5 |
| Date issued | 2024-03-15 |
| Strike | 515.7 $ |
| Maturity | Unlimited |
| Parity | 50 : 1 |
| Emission price | 4.58 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.523 € |
|---|---|
| Lowest since issue | 3.87 € |
| Spread | 0.024 € |
| Spread % | 0.46% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
803.2
USD
Average target price
850.4
USD
Spread / Average Target
+5.88%
- Stock Market
- Certificates
- OO5NB Certificat